Turn Therapeutics, a Los Angeles-based pharmaceutical and medical device company, has announced that it has received FDA clearance for its Protego antimicrobial wound dressing, which is described as a disruptive innovation to traditional petroleum saturated gauze dressings.
Protego wound dressings are single-use, sterile, antimicrobial gauze dressings impregnated with Hexagen, Turn’s petrolatum-based wound care emulsion built on the Company’s proprietary PermaFusion technology.
According to a statement, Hexagen alone carries years of successful use history for acute and chronic wound management at leading institutions. Protego, with Hexagen built in, is said to offer clinicians the same gentleness, feel, and utility as traditional, petroleum saturated gauze dressings, but with the added benefit of broad-spectrum antimicrobial protection against bacteria, fungi, and yeasts.
Bradley Burnam, CEO of Turn Therapeutics, commented: “Protego is a disruptive innovation on a nearly-century old standard of acute and chronic wound care, including post-surgical care.
“Clinicians will now have the means to dress wounds with a non-adherent contact layer similar to traditional, petroleum saturated gauze, but with broad-spectrum, antimicrobial protection. We think it could be possible to convert the current market from the traditional standard of care to Protego based on the clear added value Protego™ could bring to wound care.”
